SCHEMBL234838

SCHEMBL234838

C1=CNC[N]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1013439 0.67
SCHEMBL235060 0.67
SCHEMBL1651586 0.54
SCHEMBL235062 0.54
SCHEMBL121629 0.54
SCHEMBL515026 0.47
SCHEMBL570870 0.47
SCHEMBL108935 0.45
SCHEMBL5573422 0.42
SCHEMBL992571 0.42

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 635 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140329816-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. 2014-11-06 US claimed
EP-2736337-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI Foundation, Inc. (US) 2014-06-04 EP claimed
US-20130029988-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF EVOTEC (UK) LTD. (GB) 2013-01-31 US claimed
WO-2013016488-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF DOMINGUEZ CELIA (US) 2013-01-31 WO claimed
EP-2528441-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI Foundation, Inc. (US) 2012-12-05 EP claimed
WO-2011091153-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI, INC. (US) 2011-07-28 WO claimed
EP-2303283-A2 ANTI-CANCER COMBINATION THERAPY Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2011-04-06 EP claimed
US-20110065663-A1 ANTI-CANCER COMBINATION THERAPY KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D 2011-03-17 US claimed
US-20100240682-A1 PHOPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2010-09-23 US claimed
EP-2204192-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT Taiho Pharmaceutical Co., Ltd. (JP) 2010-07-07 EP claimed
WO-2009138507-A2 ANTI-CANCER COMBINATION THERAPY KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2009-11-19 WO claimed
EP-0884051-B1 CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES TAIHO PHARMACEUTICAL CO LTD (JP) 2004-12-15 EP claimed
EP-0763529-B1 URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME TAIHO PHARMACEUTICAL CO LTD (JP) 2003-07-23 EP claimed
US-6255314-B1 Cancerous metastasis inhibitors containing uracil derivatives TAIHO CHARMACEUTICAL CO., LTD. (JP) 2001-07-03 US claimed
EP-0884051-A1 CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1998-12-16 EP claimed
US-5744475-A 4-N-HET-METHYLURACIL DERIVATIVES; THYMIDINE PHOSPHORYLASE INHIBITORS TAIHO PHARMACEUTICAL CO., LTD. (JP) 1998-04-28 US claimed
EP-0763529-A1 URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1997-03-19 EP claimed
US-12018267-B2 Plants having increased tolerance to herbicides BASF SE (DE) 2024-06-25 US disclosed
EP-0082109-A2 Substituted 2-hydroxyphenylacetic acids and derivatives of them CIBA-GEIGY AG (CH) 1983-06-22 EP disclosed
EP-0078241-A2 Furanes CIBA-GEIGY AG (CH) 1983-05-04 EP disclosed